392 related articles for article (PubMed ID: 21560116)
1. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.
Nordal E; Zak M; Aalto K; Berntson L; Fasth A; Herlin T; Lahdenne P; Nielsen S; Straume B; Rygg M;
Arthritis Rheum; 2011 Sep; 63(9):2809-18. PubMed ID: 21560116
[TBL] [Abstract][Full Text] [Related]
2. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort.
Oen K; Duffy CM; Tse SM; Ramsey S; Ellsworth J; Chédeville G; Chetaille AL; Saint-Cyr C; Cabral DA; Spiegel LR; Schneider R; Lang B; Huber AM; Dancey P; Silverman E; Rosenberg AM; Cameron B; Johnson N; Dorval J; Scuccimarri R; Campillo S; Petty RE; Duffy KN; Boire G; Haddad E; Houghton K; Laxer R; Turvey SE; Miettunen P; Gross K; Guzman J; Benseler S; Feldman BM; Espinosa V; Yeung RS; Tucker L
Arthritis Care Res (Hoboken); 2010 Apr; 62(4):527-36. PubMed ID: 20391508
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases.
Lurati A; Salmaso A; Gerloni V; Gattinara M; Fantini F
J Rheumatol; 2009 Jul; 36(7):1532-5. PubMed ID: 19487265
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
5. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
7. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
van Dijken TD; Vastert SJ; Gerloni VM; Pontikaki I; Linnemann K; Girschick H; Armbrust W; Minden K; Prince FH; Kokke FT; Nieuwenhuis EE; Horneff G; Wulffraat NM
J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
[TBL] [Abstract][Full Text] [Related]
8. Patterns of clinical remission in select categories of juvenile idiopathic arthritis.
Wallace CA; Huang B; Bandeira M; Ravelli A; Giannini EH
Arthritis Rheum; 2005 Nov; 52(11):3554-62. PubMed ID: 16255044
[TBL] [Abstract][Full Text] [Related]
9. Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis.
Viswanath V; Myles A; Dayal R; Aggarwal A
J Rheumatol; 2011 Nov; 38(11):2482-7. PubMed ID: 21885500
[TBL] [Abstract][Full Text] [Related]
10. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria.
Berntson L; Andersson Gäre B; Fasth A; Herlin T; Kristinsson J; Lahdenne P; Marhaug G; Nielsen S; Pelkonen P; Rygg M;
J Rheumatol; 2003 Oct; 30(10):2275-82. PubMed ID: 14528529
[TBL] [Abstract][Full Text] [Related]
11. Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism.
Berntson L; Fasth A; Andersson-Gäre B; Kristinsson J; Lahdenne P; Marhaug G; Nielsen S; Pelkonen P; Svensson E;
J Rheumatol; 2001 Dec; 28(12):2737-43. PubMed ID: 11764226
[TBL] [Abstract][Full Text] [Related]
12. Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study.
Oen K; Tucker L; Huber AM; Miettunen P; Scuccimarri R; Campillo S; Cabral DA; Feldman BM; Tse S; Chédeville G; Spiegel L; Schneider R; Lang B; Ellsworth J; Ramsey S; Dancey P; Silverman E; Chetaille AL; Cameron B; Johnson N; Dorval J; Petty RE; Duffy KW; Boire G; Haddad E; Houghton K; Saint-Cyr C; Turvey SE; Benseler S; Cheang M; Yeung RS; Duffy CM
Arthritis Rheum; 2009 Aug; 61(8):1077-86. PubMed ID: 19644903
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
Minden K; Niewerth M; Zink A; Seipelt E; Foeldvari I; Girschick H; Ganser G; Horneff G
Rheumatology (Oxford); 2012 Aug; 51(8):1407-15. PubMed ID: 22447885
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
[TBL] [Abstract][Full Text] [Related]
15. Early Self-Reported Pain in Juvenile Idiopathic Arthritis as Related to Long-Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study.
Arnstad ED; Rypdal V; Peltoniemi S; Herlin T; Berntson L; Fasth A; Nielsen S; Glerup M; Ekelund M; Zak M; Aalto K; Nordal E; Romundstad PR; Rygg M;
Arthritis Care Res (Hoboken); 2019 Jul; 71(7):961-969. PubMed ID: 30055093
[TBL] [Abstract][Full Text] [Related]
16. Comparison of patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how different are they?
Butbul YA; Tyrrell PN; Schneider R; Dhillon S; Feldman BM; Laxer RM; Saurenmann RK; Spiegel L; Cameron B; Tse SM; Silverman ED
J Rheumatol; 2009 Sep; 36(9):2033-41. PubMed ID: 19648305
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease.
Grassi A; Corona F; Casellato A; Carnelli V; Bardare M
J Rheumatol; 2007 May; 34(5):1139-45. PubMed ID: 17343317
[TBL] [Abstract][Full Text] [Related]
18. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis.
Berntson L; Damgård M; Andersson-Gäre B; Herlin T; Nielsen S; Nordal E; Rygg M; Zak M; Fasth A;
J Rheumatol; 2008 Oct; 35(10):2055-61. PubMed ID: 18785306
[TBL] [Abstract][Full Text] [Related]
19. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW
Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
[TBL] [Abstract][Full Text] [Related]
20. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.
Ravelli A; Felici E; Magni-Manzoni S; Pistorio A; Novarini C; Bozzola E; Viola S; Martini A
Arthritis Rheum; 2005 Mar; 52(3):826-32. PubMed ID: 15751057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
